Results with Lifescozul™Breast Cancer
Introduction to the case
Most of the applications to the LifEscozul Protocol are for breast cancer. Because of this, it is to be expected a higher number of results for this type of cancer.
Statistics indicate that 1 in 8 women suffer from cancer during their lifetime. The factors associated with the appearance of the disease range from age (it increases as one gets older), genetics, personal factors, obesity, alcohol consumption, among others.
Symptomatology that accompanies breast cancer may include the development of a breast lump, a change in size or shape of the breast and nipple discharge.
It is important to detect any of these symptoms early by performing a self-examination and/or mammography. The advantage of early detection of this type of cancer translates into a high probability of survival, in some types above 90%.
As a curious fact, it should be noted that this type of cancer is not exclusive to women; men can also develop it, but it is rare.
The case presented today by the LifEscozul Group (escozul, blue scorpion venom, blue scorpion) is one of the most aggressive types of breast cancer: triple negative.
Triple negative breast cancer differs from other types of breast cancer in the aggressiveness of the malignant growth and that its spread is much faster. Treatment options are also more limited and it has a worse diagnosis.
Triple negative right breast cancer (moderately differentiated invasive ductal carcinoma).
Ms. Gloria was diagnosed with triple negative breast cancer, in December 2018. Her treatment options were limited and she opted for natural and alternative variants.
Thus she came to the LifEscozul Protocol in July 2019 looking for natural treatment options for her disease, and was not receiving any conventional treatment when she started with LifEscozul, the most efficient and safest formulation made from blue scorpion venom.
Evolution with LifEscozul™ and actual results
Gloria was evaluated by our Medical Group in June 2019, the recommended dosage included a gradual increase program of LifEscozul and constant follow-ups. She started in July 2019.
Since the start of treatment with LifEscozul Gloria has kept in touch with our medical side, commenting on her condition and evolution.
In August 2019 she writes to us commenting that everything was going well and that the LifEscozul treatment was causing her to have more appetite.
At the initial control in October 2019 she writes to us commenting that everything continues well and that the blood tests performed so far were normal.
At the second control in December 2019 the values remained normal, with no symptoms and remarkable quality of life with good appetite and no episodes of depression.
In the third control in January 2020 the result of the tomography with contrast performed on January 10, 2020 was received, and as a result at 5 months of treatment with LifEscozul the examination showed no changes with respect to the examination of June 2019, which indicated that the disease had been stabilized and controlled only with LifEscozul, despite being one of the most aggressive and difficult to treat types of breast cancer behavior.
During the rest of the controls in this year 2020, due to the pandemic issue Ms. Gloria has seen limited her outings, however her condition is maintained as well as her quality of life.
Triple negative breast cancer is one of the most aggressive and fast growing cancers. Treatment options are limited and it is a very difficult cancer to treat.
In Gloria's particular case, she decided not to go through conventional treatments and has been on the LifEscozul protocol (blue scorpion venom, escozul) for over a year.
During this time she has presented no negative changes in her symptomatology and the disease has not progressed.
These results are very positive and we hope to continue developing them.
We are the LifEscozul Group and the results define us.
In 2016 Hector was diagnosed with a grade I bladder carcinoma. To treat his disease they proposed chemotherapy and BCG immunotherapy, but Hector refused both treatments. View more